Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2012
04/05/2012US20120083454 Eph receptor expression in tumor stem cells
04/05/2012US20120083453 Treatment using neublastin polypeptides
04/05/2012US20120083452 Topical Anesthetic Uses of Szeto-Schiller Peptides
04/05/2012US20120083451 Composition for improving brain function and method for improving brain function
04/05/2012US20120083450 Cerebroprotein hydrolysate for treating brain injuries and neurodegenerative conditions effecting the brain
04/05/2012US20120083449 Treatment for anxiety
04/05/2012US20120083448 Parathyroid Hormone Peptides And Parathyroid Hormone-Related Protein Peptides And Methods Of Use
04/05/2012US20120083447 Novel Therapeutic Treatments Using Centhaquin
04/05/2012US20120083446 Novel albumin-free factor viii formulations
04/05/2012US20120083445 Compositions Containing HC-HA Complex and Methods of Use Thereof
04/05/2012US20120083444 Emulsion Method For Preparing Low Residual Solvent Microparticles
04/05/2012US20120083443 Control of ATP Release by Red Blood Cells and Therapeutic Applications Thereof
04/05/2012US20120083442 Myostatin binding agents
04/05/2012US20120083441 Pharmaceutical Compositions
04/05/2012US20120083440 Methods and compounds for the targeted delivery of agents to bone for interaction therewith
04/05/2012US20120083420 Compositions and methods for the treatment of immune related diseases
04/05/2012US20120083412 Composition and Method for Delivery of Substances in a Dry Mode Having a Surface Layer
04/05/2012US20120083008 Methods for obtaining molecules with reduced immunogenicity
04/05/2012US20120083004 Diagnostic Method for Celiac Sprue
04/05/2012US20120082732 Medicine for treatment of a carcinoma
04/05/2012US20120082731 Method For Removing Residual Organic Solvent From Microparticles
04/05/2012US20120082724 Dry mouldable drug formulation
04/05/2012US20120082720 Compositions For Treating Chronic Viral Infections
04/05/2012US20120082717 Complex, multilayer using the same, and device coated with the multilayer
04/05/2012US20120082715 Stabilized products, processes and devices for preparing the same
04/05/2012US20120082706 Medical device for drug delivery
04/05/2012US20120082700 Compositions for stimulation of mammalian innate immune resistance to pathogens
04/05/2012US20120082690 Chaperonin 10 immunosuppression
04/05/2012US20120082677 Compositions for the treatment of hcv and hbv
04/05/2012US20120082676 Methods for preventing and treating angioedema
04/05/2012US20120082675 Insulin-like growth factor signaling and integrin
04/05/2012US20120082673 Human cytokine receptor
04/05/2012US20120082672 Botulinum Neurotoxin B Receptors and Use Thereof
04/05/2012US20120082671 Modulation of activity of neurotrophins
04/05/2012US20120082668 Soluble il-17ra/rc fusion proteins and related methods
04/05/2012US20120082659 Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
04/05/2012US20120082658 Methods for the Treatment of Allergic Diseases
04/05/2012US20120082656 Composition comprising the purified extract of bee venom for preventing and treating degenerative brain disease
04/05/2012US20120082655 Downregulation of SPY1 by p53 as an essential component of p53-mediated effects
04/05/2012US20120082653 Methods of lysosomal storage disease therapy
04/05/2012US20120082650 Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
04/05/2012US20120082649 Perivascular mesenchymal precursor cells
04/05/2012US20120082647 Interferon-beta for use as monotherapy or in combination with other cancer therapies
04/05/2012US20120082646 Antiviral Compounds And Uses Thereof
04/05/2012US20120082645 2'-c-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions, and uses thereof
04/05/2012US20120082644 Cytokines and neuroantigens for treatment of immune disorders
04/05/2012US20120082643 Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response
04/05/2012US20120082642 Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
04/05/2012US20120082641 Formulations for bovine granulocyte colony stimulating factor and variants thereof
04/05/2012US20120082636 Stabilized alpha helical peptides and uses thereof
04/05/2012US20120082619 Labelled adrenomedullin derivatives and their use for imaging and therapy
04/05/2012US20120082618 Prostate cancer diagnosis and treatment
04/05/2012CA2813467A1 Minimizing intestinal dysfunction
04/05/2012CA2813335A1 Process for purifying cyclolipopeptide compounds or salts thereof
04/05/2012CA2813304A1 Interferon-beta for use as monotherapy or in combination with other cancer therapies
04/05/2012CA2813302A1 Emulsion method for preparing low residual solvent microparticles
04/05/2012CA2813301A1 Method for removing residual organic solvent from microparticles
04/05/2012CA2813253A1 Method of preparing a dry powder from a water bacteria extract-concentrate
04/05/2012CA2813101A1 Eph receptor expression in tumor stem cells
04/05/2012CA2813056A1 N-carboxyalkyl auristatins and the use thereof
04/05/2012CA2813013A1 Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
04/05/2012CA2812901A1 Cyclosporine emulsion
04/05/2012CA2812870A1 Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
04/05/2012CA2812862A1 Enteric coated, low-strength pancrelipase formulations
04/05/2012CA2812510A1 Pharmaceutical composition
04/05/2012CA2812057A1 Compositions and methods for treatment of hematological malignancies
04/05/2012CA2811977A1 Method of achieving a thymosin beta 4 concentration in a human patient
04/05/2012CA2810712A1 Skin collagen production-promoting agent
04/05/2012CA2810641A1 Skin collagen production-promoting agent
04/05/2012CA2809916A1 Polypeptides having endopeptidase activity and polynucleotides encoding same
04/05/2012CA2809496A1 Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof
04/04/2012EP2436765A2 Recombinant factor X with no glycosylation and method for preparing the same
04/04/2012EP2436695A1 Methods for treating and preventing fibrosis by IL-21 / IL-21R antagonists
04/04/2012EP2436688A1 Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide
04/04/2012EP2436394A1 Peptide therapy
04/04/2012EP2436393A1 Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
04/04/2012EP2436392A1 Use of midkine and medical device containing midkine
04/04/2012EP2436391A2 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
04/04/2012EP2436390A1 Topical Anesthetic Uses of Szeto-Schiller Peptides
04/04/2012EP2436389A1 Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof
04/04/2012EP2436387A1 Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
04/04/2012EP2435573A2 Expression of recombinant proteins
04/04/2012EP2435562A1 Compositions and methods for production of aglycosylated plasminogen
04/04/2012EP2435477A1 Antigen-binding proteins
04/04/2012EP2435470A1 Muteins of the pyrroline-5-carboxylate reductase 1
04/04/2012EP2435468A2 Fibromodulin peptide
04/04/2012EP2435087A2 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
04/04/2012EP2435086A1 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
04/04/2012EP2435076A1 Anti-ck8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes
04/04/2012EP2435070A2 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin
04/04/2012EP2435069A1 Lipoxygenase and its use in wound healing
04/04/2012EP2435068A2 Use of 2 anti-sparc antibodies to predict response to chemotherapy
04/04/2012EP2435067A2 Stem cell targeting
04/04/2012EP2435065A1 Cyclosporin derivatives for treating inflammatory diseases and conditions
04/04/2012EP2435064A1 Use of hat inhibitors and tmprss2 inhibitors as medicaments
04/04/2012EP2435063A2 Moraxella catarrhalis antigens
04/04/2012EP2435062A1 Inhibition 0f inflammation using antagonists of muc1
04/04/2012EP2435061A1 Glp-1 receptor agonist compounds for sleep enhancement
04/04/2012EP2435060A1 Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans
04/04/2012EP2435059A1 Novel peptides, process for preparation thereof, and use thereof
1 ... 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 ... 3163